Group 1: Stock Performance and Price Targets - Brainsway Ltd. Sponsored ADR (BWAY) closed at $9.89, with a 5.9% gain over the past four weeks, and a mean price target of $13.73 indicating a 38.8% upside potential [1] - The average price targets range from a low of $12.50 to a high of $16, with a standard deviation of $1.56, suggesting a 26.4% increase at the lowest estimate and a 61.8% increase at the highest [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [7] Group 2: Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about BWAY's earnings prospects, with strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has increased by 67.6% due to one estimate moving higher over the last 30 days without any negative revisions [10] - BWAY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [11] Group 3: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - While price targets are commonly sought after, they can mislead investors more often than guide them accurately [5] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8]

Group 1: Company Highlights - Brainsway (BWAY) is a commercial stage medical device company focused on non-invasive neuromodulation products, with a 60% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Grupo Televisa (TV) is the largest media company in the Spanish-speaking world, experiencing a 22.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - ICU Medical (ICUI) develops innovative medical devices for vascular therapy, oncology, and critical care, with a 7.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - Sally Beauty (SBH) is an international specialty retailer of professional beauty supplies, seeing a 6.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - PHINIA Inc. (PHIN) provides premium solutions and components in manufacturing, with a 5.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4] Group 2: Investment Opportunities - The stocks mentioned have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment [1][2][3][4]

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation (TMS) technology to treat alcohol use disorder (AUD) patients. The outcomes were reported in ...

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS™) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer ...

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steven Lichtman - Oppenheimer Jeff Cohen - Ladenburg Thalmann & Company Operator Good day, and welcome to the BrainsWay Third Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Brian Ritchie of Life ...

Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided an operatio ...

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the ...

Group 1: Stock Performance and Price Targets - Brainsway Ltd. Sponsored ADR (BWAY) shares have increased by 24.2% over the past four weeks, closing at $10.06, with a mean price target of $13.28 indicating a potential upside of 32% [1] - The lowest price target is $12, suggesting a 19.3% increase, while the highest target is $16, indicating a potential surge of 59.1% [1] - The standard deviation of the price targets is $1.84, reflecting the variability and agreement among analysts [1] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising BWAY's earnings estimates higher, which correlates with potential stock price increases [5] - The Zacks Consensus Estimate for the current year has risen by 4.2% over the past month, with one estimate increasing and no negative revisions [5] - BWAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [5] Group 3: Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [2][3] - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [4] - While price targets should not be ignored, they should be approached with skepticism to avoid disappointing returns on investment [4][6]

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Brainsway Ltd. Sponsored ADR (BWAY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Brainsway Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #3. The Z ...